{"gene":"TGFBR3","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1993,"finding":"Betaglycan (TGFBR3) presents TGF-β directly to the type II signaling receptor kinase, forming a high-affinity ternary complex. Membrane betaglycan increases TGF-β binding to the signaling receptor, enhances cell responsiveness to TGF-β, and eliminates biological differences between TGF-β isoforms.","method":"Affinity labeling, cross-linking, cell-based binding assays, bioassays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — foundational study with multiple orthogonal methods, >800 citations, replicated extensively","pmids":["8391934"],"is_preprint":false},{"year":1991,"finding":"Betaglycan is a membrane-anchored proteoglycan with an extracellular domain carrying glycosaminoglycan chains; its ectodomain can be shed as a soluble proteoglycan. The transmembrane and cytoplasmic regions share homology with endoglin. GAG chains are dispensable for TGF-β binding to the core protein.","method":"cDNA cloning, structural analysis, biochemical characterization","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — primary structure determination with functional domain analysis, >600 citations","pmids":["1657406"],"is_preprint":false},{"year":1989,"finding":"Betaglycan exists in both membrane-bound and soluble forms; the membrane form is hydrophobic and associates with liposomes, while soluble forms lack a membrane anchor. Both bind TGF-β via the core protein and carry heparan sulfate and/or chondroitin sulfate GAG chains.","method":"Affinity labeling, liposome association assay, biochemical fractionation","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 — original identification with multiple biochemical methods, >330 citations","pmids":["2592419"],"is_preprint":false},{"year":1994,"finding":"TGF-β binds to the NH2-terminal endoglin-related region of betaglycan. GAG attachment sites are Ser535 and Ser546 in the uromodulin-related region; their mutation prevents GAG attachment but does not affect TGF-β binding or presentation. Soluble betaglycan (lacking membrane anchor) cannot present TGF-β to the type II receptor and instead acts as a potent inhibitor of TGF-β, particularly the TGF-β2 isoform.","method":"Site-directed mutagenesis, deletion mutagenesis, cell-based binding assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional readouts, >340 citations","pmids":["8106553"],"is_preprint":false},{"year":2000,"finding":"Betaglycan functions as an inhibin co-receptor with ActRII. Betaglycan binds inhibin with high affinity, enhances inhibin binding in cells co-expressing ActRII and betaglycan, and inhibin forms crosslinked complexes with both betaglycan and ActRII. Betaglycan confers inhibin sensitivity to cell lines that otherwise respond poorly, mediating functional antagonism of activin signaling.","method":"Receptor binding assays, cross-linking, co-expression, functional antagonism assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods, >470 citations, replicated by multiple labs","pmids":["10746731"],"is_preprint":false},{"year":1992,"finding":"Betaglycan binds bFGF via its heparan sulfate chains (separate from the TGF-β binding core protein domain). bFGF treatment of osteoblasts selectively reduces heparan sulfate GAG content of betaglycan without affecting chondroitin sulfate or core protein, demonstrating ligand-regulated remodeling of the bFGF-binding domain.","method":"Affinity labeling, GAG composition analysis, cell-based ligand binding","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple methods demonstrating dual-ligand binding at distinct domains, >125 citations","pmids":["1556106"],"is_preprint":false},{"year":2001,"finding":"Betaglycan ectodomain contains two independent TGF-β binding domains: the NH2-terminal endoglin-related region and the COOH-terminal uromodulin-related region. Only the endoglin-related region mediates TGF-β presentation to TGF-β type II receptor. The uromodulin-related region specifically binds inhibin A with relative affinities TGF-β2 > inhibin A > TGF-β1.","method":"Deletion mutagenesis, ligand binding competition, Smad2 phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — domain mutagenesis with multiple functional readouts","pmids":["11278442"],"is_preprint":false},{"year":2001,"finding":"Recombinant soluble betaglycan is a homodimer (two 110 kDa monomers, non-covalent) lacking GAG chains. It binds TGF-β isoforms with relative affinities TGF-β2 > TGF-β3 > TGF-β1, with Kd ~3.5 nM for TGF-β1, and neutralizes TGF-β activity with 10-fold higher potency against TGF-β2 than TGF-β1.","method":"Baculovirus expression, biochemical characterization, bioassay","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — reconstituted recombinant protein with quantitative binding and functional data","pmids":["11256966"],"is_preprint":false},{"year":2001,"finding":"In LLC-PK1 renal epithelial cells (which lack endogenous betaglycan), expressed betaglycan inhibits TGF-β signaling by preventing type I–type II receptor complex formation, not by ligand sequestration. This inhibitory effect is mediated by the glycosaminoglycan modifications; a GAG-deficient betaglycan mutant does not inhibit signaling or receptor association.","method":"Reporter gene assay, thymidine incorporation, Smad2/3 phosphorylation, co-immunoprecipitation of receptor complexes, GAG mutant","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple functional readouts, mutagenesis, mechanistically distinct finding","pmids":["11668175"],"is_preprint":false},{"year":2003,"finding":"Betaglycan shedding (release of the soluble ectodomain) is induced by pervanadate (a tyrosine phosphatase inhibitor) and generates a 90 kDa fragment (sBG-90) whose production is mediated by MT1-MMP (membrane type-1 matrix metalloprotease). MT3-MMP can also generate this fragment. The released sBG-90 retains preferential binding to TGF-β2 over TGF-β1.","method":"Overexpression of MT-MMPs in COS-1 cells, metalloprotease inhibitors, binding competition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — mechanistic identification of shedding protease with overexpression and inhibitor experiments","pmids":["14672946"],"is_preprint":false},{"year":1993,"finding":"A fragment of betaglycan ectodomain (amino acids 543–769) near the transmembrane domain binds TGF-β and at low concentrations enhances TGF-β binding to the type II receptor. The same site is competed by decorin, biglycan, and fibromodulin, indicating overlapping binding interfaces in TGF-β.","method":"Recombinant fusion protein expression, competition binding assay, affinity cross-linking, bioassay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — recombinant domain mapping with quantitative binding and functional data","pmids":["8226781"],"is_preprint":false},{"year":2006,"finding":"Betaglycan domain spanning amino acids 591–700 (within the ZP domain) is the only inhibin-binding region. The inhibin and TGF-β binding residues overlap; Val614Tyr mutation abolishes inhibin binding but retains TGF-β binding via the N-terminal site. Betaglycan V614Y mutants fail to mediate inhibin antagonism of activin signaling but can still present TGF-β to TβRII, functionally separating the two co-receptor activities.","method":"Deletion and point mutagenesis, ligand binding assays, functional antagonism reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — point mutagenesis with functional separation of two activities","pmids":["16621788"],"is_preprint":false},{"year":2006,"finding":"Betaglycan can signal in a TGF-β ligand-independent manner through activation of the p38 MAPK pathway, requiring its cytoplasmic domain. This effect increases TGF-β target gene expression (fibronectin, CTGF) and inhibits myogenin in myoblasts independently of Smad2 phosphorylation.","method":"Adenoviral overexpression, reporter assays, TGF-β blocking antibodies, p38 inhibitor, cytoplasmic domain mutant","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 — multiple reporter/inhibitor experiments in single lab","pmids":["16413747"],"is_preprint":false},{"year":2009,"finding":"Betaglycan ectodomain has a bilobular structure; each lobe folds independently and binds TGF-β through distinct non-overlapping interfaces. High-affinity TGF-β binding (Kd low nanomolar) requires both domains tethered together; individual domains bind 1–2 orders of magnitude more weakly. Plasmin cleaves betaglycan between the two domains, separating them and abolishing neutralizing activity.","method":"Plasmin proteolysis, N-terminal sequencing, surface plasmon resonance, TGF-β activity bioassay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted fragments with SPR quantitation and functional assays","pmids":["19842711"],"is_preprint":false},{"year":2011,"finding":"Crystal structure of the betaglycan ZP-C domain (2.0 Å resolution) reveals an immunoglobulin-like fold. The external hydrophobic patch is integral to ZP-C (corresponds to ZP-C G strand). The AB loop and convex surface pocket are important for TGF-β ligand binding. Absence of the maturation cleavage site (present in polymerizing ZP proteins) explains why betaglycan does not polymerize.","method":"X-ray crystallography at 2.0 Å resolution","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with structural-functional interpretation","pmids":["21402931"],"is_preprint":false},{"year":2016,"finding":"Betaglycan binds TGF-β homodimers with 1:1 stoichiometry allowing one TβRII to bind simultaneously. Betaglycan modestly potentiates TβRII binding to TGF-β2 but must be displaced for TβRI to bind. This defines a hand-off mechanism: betaglycan concentrates TGF-β2 on the cell surface, promotes TβRII binding by membrane-localization and allostery, and is subsequently displaced by TβRI recruitment.","method":"Surface plasmon resonance, isothermal titration calorimetry, size-exclusion chromatography","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple biophysical methods defining stoichiometry and mechanism","pmids":["27951653"],"is_preprint":false},{"year":2018,"finding":"NMR titrations and SPR identified the BGZP-C binding site on TGF-β2 as the inner concave surface of its extended finger region, involving residues Ile-92, Lys-97, and Glu-99 specific to TGF-β isoforms and inhibin-α. Mutation of these residues to the BMP-2 equivalents reduces BGZP-C binding, explaining betaglycan selectivity for TGF-βs and inhibin A over BMPs.","method":"NMR (methyl-labeled TGF-β2), surface plasmon resonance, site-directed mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structural mapping with mutagenesis and SPR validation","pmids":["30598510"],"is_preprint":false},{"year":2025,"finding":"Cryo-EM/structural determination of TGF-β bound simultaneously to betaglycan and the signaling receptors TGFBR1 and TGFBR2 reveals key ligand engagement interfaces distinct from those of endoglin. The structure explains the hand-off mechanism: betaglycan binds TGF-β, facilitates signaling receptor assembly, then is displaced as signaling receptors engage.","method":"Cryo-EM/structural biology with functional validation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — near-atomic structure of complete receptor complex explaining mechanism","pmids":["40011426"],"is_preprint":false},{"year":2013,"finding":"Glucocorticoids (dexamethasone) upregulate Tgfbr3 expression in lung fibroblasts, and Tgfbr3 functions as a signaling switch that blunts Tgfbr1/Smad2/3 signaling while potentiating Acvrl1/Smad1/5/8 signaling, driving TGF-β-dependent myofibroblast differentiation (smooth muscle actin and myosin acquisition) in a Smad1-dependent manner.","method":"Dexamethasone treatment, siRNA knockdown, reporter assays, in vivo mouse lung experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including in vivo validation","pmids":["24347165"],"is_preprint":false},{"year":2010,"finding":"Inhibin-A antagonizes TGFβ2 signaling by inducing clathrin-independent endocytic internalization of betaglycan, reducing available cell-surface betaglycan binding sites for TGFβ2. This is distinct from TGFβ-induced betaglycan internalization and depends on mutual affinity of inhibin-A and TGFβ2 for betaglycan.","method":"Cell-surface binding assay, endocytosis inhibitors, functional signaling assays in adrenocortical cells","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistically novel finding with pharmacological and functional evidence in single lab","pmids":["20160125"],"is_preprint":false},{"year":2009,"finding":"Betaglycan is an endogenous obligate co-receptor for high-potency inhibin antagonism of activin signaling in rat anterior pituitary gonadotropes. RNAi knockdown and immunoneutralization of betaglycan each independently reduce the potency of inhibin-A antagonism of activin-induced FSH secretion by >1000-fold.","method":"siRNA knockdown, neutralizing antibody, primary gonadotrope cultures, FSH secretion assay","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — two independent loss-of-function approaches with quantitative FSH secretion readout","pmids":["19372236"],"is_preprint":false},{"year":2018,"finding":"Conditional knockout of Tgfbr3 specifically in murine gonadotropes impairs inhibin A (but not inhibin B) suppression of FSH synthesis in cultured pituitaries, demonstrating that TGFBR3 is an inhibin A-specific co-receptor in vivo in gonadotropes. Conditional knockout females are super-fertile with enhanced folliculogenesis.","method":"Conditional knockout mouse model (gonadotrope-specific Cre), FSH secretion assay, pituitary culture","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — clean conditional KO with specific isoform-selective phenotypic readout","pmids":["30364975"],"is_preprint":false},{"year":1994,"finding":"Plasmin selectively cleaves betaglycan on intact cells, releasing a 60 kDa TGF-β-betaglycan complex into the medium. The type I and type II TGF-β receptors are not plasmin substrates. Plasmin-treated cells release more active TGF-β, indicating betaglycan cleavage liberates active growth factor.","method":"Affinity labeling, SDS-PAGE of cell surface receptors, TGF-β bioassay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 — direct protease substrate identification with functional consequence","pmids":["8068006"],"is_preprint":false},{"year":2012,"finding":"Granzyme B cleaves soluble betaglycan (along with decorin and biglycan) and releases active TGF-β1 from these proteoglycans. The released TGF-β1 retains activity, inducing SMAD-3 phosphorylation in human coronary artery smooth muscle cells.","method":"In vitro cleavage assay, cytokine release assay, SMAD3 phosphorylation, granzyme B inhibitor","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro reconstitution with functional signaling readout","pmids":["22479366"],"is_preprint":false},{"year":2000,"finding":"On human microvascular endothelial cells, endoglin associates with betaglycan in a complex that can form in a ligand-dependent or ligand-independent manner. Three higher-order complexes containing endoglin with type I and/or type II TGF-β receptors are also present.","method":"Co-immunoprecipitation, affinity labeling with radiolabeled TGF-β","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 — co-IP and affinity labeling demonstrating complex formation","pmids":["10951214"],"is_preprint":false},{"year":2003,"finding":"On human chondrocytes, endoglin forms a heteromeric complex with betaglycan in both a ligand-independent and ligand-dependent manner, independent of the type II TGF-β receptor, as shown by co-immunoprecipitation at endogenous receptor concentrations.","method":"Co-immunoprecipitation, affinity labeling with radiolabeled TGF-β","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 3 — reciprocal co-IP demonstrating endogenous complex","pmids":["12568406"],"is_preprint":false},{"year":1998,"finding":"Betaglycan overexpression in rat myoblasts enhances TGF-β inhibition of proliferation and PAI-1 synthesis, and specifically increases TGF-β binding to the type II receptor (~3.5-fold). Endoglin overexpression has weaker and distinct effects (increases binding to both type I and II receptors). The differential effects reside in the extracellular domain, shown by chimeric protein analysis.","method":"Overexpression, 125I-TGF-β affinity cross-linking, proliferation assay, chimeric protein analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct comparison using chimeric receptors with quantitative binding and functional data","pmids":["9830054"],"is_preprint":false},{"year":2010,"finding":"Betaglycan's transmembrane-cytoplasmic fragment remaining after ectodomain shedding is stable in cells and is a substrate of γ-secretase. γ-Secretase inhibition or expression of the transmembrane-cytoplasmic fragment blunts TGF-β2 signaling in HepG2 cells.","method":"γ-Secretase inhibitors, shedding inhibitor TAPI-2, transfection, TGF-β signaling reporter","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological identification of γ-secretase cleavage with functional consequence","pmids":["21167215"],"is_preprint":false},{"year":2009,"finding":"Tgfbr3 (betaglycan) knockout mice show defective seminiferous cord formation, reduced fetal Leydig cell function (decreased Insl3, Cyp17a1, Cyp11a1, Star, Hsd3b1 expression), and reduced Sertoli cell markers (Dhh, Sox9, Amh) without changes in Leydig cell number, indicating betaglycan is required for normal fetal testis structure and endocrine function.","method":"Knockout mouse model, immunohistochemistry, quantitative RT-PCR, whole-mount in situ hybridization, morphometry","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 — clean null KO with multiple molecular and morphological phenotypic readouts","pmids":["19696014"],"is_preprint":false},{"year":2011,"finding":"Betaglycan heterozygous knockout mice have augmented nephron number and accelerated ureteric branching, while null mice show renal hypoplasia and reduced nephron number. Opposing molecular phenotypes involve altered expression of Bmp4, Pax2, Gdnf, Ret, Wnt4 and other metanephric regulatory genes, demonstrating dose-sensitive betaglycan requirement for kidney development.","method":"Knockout and heterozygous mouse models, stereological nephron counting, quantitative RT-PCR","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — both null and heterozygous models with quantitative morphological and molecular phenotyping","pmids":["21533152"],"is_preprint":false},{"year":2016,"finding":"TGFBR3/betaglycan, independent of its TGF-β co-receptor function, regulates canonical Wnt3a signaling through its GAG chains: heparan sulfate chains sequester Wnt3a and inhibit Wnt signaling, while chondroitin sulfate chains promote Wnt3a signaling. The two GAG modifications have opposing effects on Wnt availability.","method":"GAG mutant constructs, Wnt reporter assays, ligand binding experiments","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — novel TGF-β-independent function demonstrated with GAG mutants and functional reporters","pmids":["27784788"],"is_preprint":false},{"year":2008,"finding":"The inhibin A binding site on betaglycan maps to an epitope on the outer convex surface of the inhibin α-subunit (residues Val108–Tyr120). Simultaneous substitution of Thr111, Ser112, and Tyr120 to alanine abolishes betaglycan binding and prevents inhibin A suppression of activin-induced FSH release from rat pituitary cells.","method":"Site-directed mutagenesis of inhibin A, binding assay, pituitary cell bioassay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis identifying binding epitope validated by functional FSH assay","pmids":["18397882"],"is_preprint":false},{"year":2007,"finding":"Loss of betaglycan expression in ovarian cancer cells is partly due to epigenetic silencing (reversed by 5-aza-2'-deoxycytidine and trichostatin A combination). Restoring betaglycan in Ovca429 cells inhibits cancer cell motility and invasiveness, and enhances antimigratory effects of inhibin and inhibin-mediated repression of MMP levels.","method":"Epigenetic drug treatment, stable transfection, motility/invasion assays, MMP measurement","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — restoration-of-function with defined cellular phenotypes","pmids":["17522389"],"is_preprint":false},{"year":2014,"finding":"TGFBR3 forms a complex with β-arrestin 2 scaffolding protein and IκBα. Overexpression of TGFBR3 decreases p-p65 and increases IκBα expression, inhibiting NF-κB signaling; this effect is abolished by β-arrestin 2 knockdown. This pathway inhibits EMT and migration in oral squamous cell carcinoma cells.","method":"Co-immunoprecipitation, overexpression, siRNA knockdown, migration/invasion assays","journal":"Cell adhesion & migration","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP identifying complex, functional epistasis by β-arrestin knockdown","pmids":["29130787"],"is_preprint":false},{"year":2019,"finding":"TGFBR3 induces secretion of angiogenin (ANG), and ANG is required and sufficient to mediate TGFBR3-dependent inhibition of migration and invasion in SMAD4-positive oral cancer cells. In SMAD4-deficient cells, TGFBR3 suppression requires GIPC1 (but not ARRB2), indicating SMAD4-dependent and -independent mechanisms.","method":"Overexpression, KD of ARRB2/GIPC1, migration/invasion assays, SMAD4-null cell comparison","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — multiple loss-of-function experiments identifying SMAD4-dependent and independent pathways","pmids":["32471132"],"is_preprint":false},{"year":2018,"finding":"Loss of TGFBR3 in clear-cell renal cell carcinoma increases ALDH-positive cancer-initiating cell populations (TGF-β-dependent), and independently enhances cell migration via FAK-PI3K signaling with increased lamellipodium formation, demonstrating TGF-β-dependent and TGF-β-independent metastatic mechanisms of TGFBR3.","method":"Orthotopic inoculation in mice, ALDH flow cytometry, FAK-PI3K inhibitors, migration assay, stable KD","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro assays with pathway-specific inhibitors","pmids":["29391598"],"is_preprint":false},{"year":2014,"finding":"Lactoferrin directly interacts with betaglycan (TGFBR3) and induces formation of the TGFBR3/TβRII/TβRI complex, leading to Smad3 phosphorylation and IgA isotype switching in B cells. Retinoic acid further augments this by increasing betaglycan expression.","method":"Direct binding assay, co-immunoprecipitation of receptor complex, Smad3 phosphorylation, IgA reporter assay, in vivo peroral administration","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding and receptor complex assembly with functional IgA readout","pmids":["25492477"],"is_preprint":false},{"year":2019,"finding":"Betaglycan loss in mesenchymal stromal cells augments TGF-β signaling, proliferation, and migration, and completely blocks osteoblast differentiation. Betaglycan controls expression of Wnt5a (>60-fold increase upon loss), which activates canonical Wnt signaling to impair osteogenesis. A Wnt5a neutralizing antibody rescues osteogenic gene expression in betaglycan-ablated MSCs.","method":"siRNA knockdown, recombinant Wnt5a addition, neutralizing antibody, osteogenic differentiation assay, in vivo xenograft model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with mechanistic rescue by neutralizing antibody and in vivo validation","pmids":["31409900"],"is_preprint":false},{"year":2019,"finding":"TGFBR3 is identified as a target of let-7 microRNA. Induction of Tgfbr3 in cardiomyocytes causes apoptosis through p38 MAPK activation. In vivo AAV9-mediated let-7 knockdown exacerbates cardiomyocyte apoptosis after myocardial infarction, while let-7 overexpression reduces it.","method":"AAV9-mediated microRNA overexpression/knockdown in mice, apoptosis assays, p38 MAPK measurement","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo AAV experiment linking TGFBR3 to p38 MAPK apoptosis pathway","pmids":["31401194"],"is_preprint":false},{"year":2002,"finding":"TGF-β competes with inhibin A for binding to betaglycan on gonadotrope LβT2 cells, thereby reversing inhibin A antagonism of activin-induced FSHβ and GnRHR promoter activity. Immunoprecipitation confirmed TGF-β1 and TGF-β2 compete with inhibin A for betaglycan binding.","method":"Radiolabeled inhibin A competition binding, co-immunoprecipitation of receptor complexes, luciferase reporter assay","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — direct competition binding and functional reporter data","pmids":["12456797"],"is_preprint":false},{"year":2002,"finding":"Betaglycan promoter is regulated by MyoD (but not myogenin) and retinoic acid (upregulation) and by TGF-β isoforms (downregulation). Betaglycan expression is upregulated during C2C12 myoblast-to-myotube differentiation, and forced betaglycan expression increases TGF-β2 responsiveness in myoblasts.","method":"Northern/Western blot during differentiation, promoter cloning and reporter assay, transcription factor overexpression, affinity labeling, immunofluorescence","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — promoter characterization with multiple transcription factor experiments and functional validation","pmids":["12399463"],"is_preprint":false},{"year":2011,"finding":"TGFBR3 overexpression in cardiac fibroblasts prevents hypoxia-induced apoptosis by attenuating TGF-β1/p-Smad2/3 signaling, blocking TGFBR1-TGFBR2 complex formation, reversing Bax upregulation and Bcl-2 downregulation, and inhibiting hypoxia-induced calcium influx.","method":"Overexpression, MTT assay, TUNEL, co-immunoprecipitation of receptor complex, calcium imaging","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression with multiple mechanistic readouts including receptor complex IP","pmids":["21792916"],"is_preprint":false}],"current_model":"TGFBR3 (betaglycan) is a membrane-anchored proteoglycan co-receptor that presents TGF-β (particularly TGF-β2) to the type II signaling receptor by forming a ternary complex, potentiating receptor assembly; its shed soluble ectodomain acts as a TGF-β antagonist; it functions as an obligate inhibin A co-receptor by binding inhibin A via its ZP (uromodulin-related) domain and facilitating ternary complex formation with activin type II receptors to antagonize activin signaling; the GAG chains mediate bFGF binding and can independently regulate Wnt signaling and TβRI/TβRII complex formation; γ-secretase processes the remaining transmembrane fragment after shedding; and betaglycan can signal in a TGF-β-independent manner through p38 MAPK via its cytoplasmic domain."},"narrative":{"teleology":[{"year":1989,"claim":"Before the molecular identity of the type III TGF-β receptor was known, this study established that betaglycan exists as both membrane-bound and soluble proteoglycan forms that bind TGF-β via core protein carrying heparan sulfate and chondroitin sulfate GAG chains.","evidence":"Affinity labeling, liposome association, and biochemical fractionation of cell-derived betaglycan","pmids":["2592419"],"confidence":"High","gaps":["Molecular cloning not yet achieved","Functional role of GAG chains unknown","Mechanism of soluble form generation undefined"]},{"year":1991,"claim":"cDNA cloning revealed betaglycan as a transmembrane proteoglycan with an ectodomain carrying GAG chains and a cytoplasmic domain homologous to endoglin, establishing that GAG chains are dispensable for TGF-β binding to the core protein.","evidence":"cDNA cloning, structural domain analysis, biochemical characterization","pmids":["1657406"],"confidence":"High","gaps":["Function of cytoplasmic domain unknown","Mechanism of TGF-β presentation not yet demonstrated"]},{"year":1992,"claim":"Discovery that betaglycan binds bFGF through its heparan sulfate chains at a site distinct from the TGF-β-binding core protein established betaglycan as a dual-ligand co-receptor with ligand-regulated GAG remodeling.","evidence":"Affinity labeling and GAG composition analysis in osteoblasts","pmids":["1556106"],"confidence":"High","gaps":["Functional consequences of bFGF–betaglycan interaction for FGF signaling unclear","In vivo relevance not tested"]},{"year":1993,"claim":"The central co-receptor mechanism was established: membrane betaglycan directly presents TGF-β to the type II signaling receptor in a ternary complex, enhancing cell responsiveness and equalizing isoform-specific differences, while a recombinant ectodomain fragment could enhance TGF-β binding to TGFBR2 at low concentrations.","evidence":"Affinity labeling, cross-linking, cell-based binding, and bioassays; recombinant fragment competition binding","pmids":["8391934","8226781"],"confidence":"High","gaps":["Stoichiometry and structural basis of ternary complex unknown","Mechanism of TGF-β handoff to signaling receptors undefined"]},{"year":1994,"claim":"Domain mapping showed TGF-β binds the N-terminal endoglin-related region; GAG attachment sites were identified at Ser535/Ser546 in the uromodulin-related region. Critically, soluble betaglycan cannot present TGF-β and instead acts as a potent inhibitor, particularly of TGF-β2, establishing soluble betaglycan as a natural antagonist.","evidence":"Site-directed and deletion mutagenesis with cell-based binding and functional assays; plasmin cleavage releasing TGF-β–betaglycan complexes from cells","pmids":["8106553","8068006"],"confidence":"High","gaps":["Protease(s) mediating physiological shedding not identified","In vivo antagonist function of soluble betaglycan unconfirmed"]},{"year":2000,"claim":"A second major co-receptor function was discovered: betaglycan binds inhibin A with high affinity and, together with ActRII, confers inhibin sensitivity to cells, mediating functional antagonism of activin signaling — establishing betaglycan as a bifunctional co-receptor for both TGF-β and inhibin.","evidence":"Receptor binding assays, cross-linking, co-expression, and functional antagonism assays; co-IP showing endoglin–betaglycan complex on endothelial cells","pmids":["10746731","10951214"],"confidence":"High","gaps":["Inhibin binding domain on betaglycan not mapped","Whether inhibin and TGF-β compete for betaglycan unknown"]},{"year":2001,"claim":"The ectodomain was shown to contain two independent TGF-β-binding domains — the N-terminal endoglin-related region mediating presentation to TGFBR2 and the C-terminal uromodulin-related region binding both TGF-β2 and inhibin A. Separately, GAG chains were found to inhibit TGF-β signaling by preventing TGFBR1–TGFBR2 complex formation in specific cell contexts.","evidence":"Deletion mutagenesis with Smad2 phosphorylation readouts; GAG-deficient mutants in LLC-PK1 cells with reporter and receptor co-IP assays; recombinant soluble betaglycan characterization by SPR and bioassay","pmids":["11278442","11668175","11256966"],"confidence":"High","gaps":["Structural basis of each domain's ligand binding unknown","How context determines whether betaglycan promotes or inhibits signaling unresolved"]},{"year":2002,"claim":"TGF-β and inhibin A were shown to compete for betaglycan binding on gonadotrope cells, with TGF-β reversing inhibin antagonism of activin-induced FSH gene expression, linking the two co-receptor functions through a shared binding surface.","evidence":"Radiolabeled inhibin A competition binding, receptor co-IP, and luciferase reporter in LβT2 cells","pmids":["12456797"],"confidence":"Medium","gaps":["Molecular basis of competition not resolved at residue level","In vivo physiological significance of TGF-β–inhibin competition for betaglycan undetermined"]},{"year":2003,"claim":"MT1-MMP was identified as the protease mediating betaglycan ectodomain shedding, generating a 90 kDa soluble fragment retaining TGF-β2-preferential binding, providing a mechanism for regulated production of the soluble antagonist form.","evidence":"Overexpression of MT-MMPs in COS-1 cells with metalloprotease inhibitors and binding competition","pmids":["14672946"],"confidence":"High","gaps":["Physiological stimuli triggering shedding in vivo not identified","Fate of remaining transmembrane fragment not explored"]},{"year":2006,"claim":"The inhibin-binding site was mapped to residues 591–700 within the ZP domain, with Val614 critical for inhibin but not TGF-β binding, enabling functional separation of inhibin co-receptor and TGF-β presentation activities. Separately, betaglycan was found to signal independently of TGF-β ligand through p38 MAPK via its cytoplasmic domain.","evidence":"Point mutagenesis (V614Y) with binding and functional reporter assays; adenoviral overexpression with p38 inhibitor and TGF-β blocking antibodies","pmids":["16621788","16413747"],"confidence":"High","gaps":["Structural basis of ZP domain–inhibin interface not resolved","Cytoplasmic domain signaling partners for p38 activation unknown"]},{"year":2008,"claim":"The reciprocal inhibin epitope for betaglycan binding was mapped to the inhibin α-subunit outer convex surface (Val108–Tyr120), with triple alanine substitution abolishing betaglycan-dependent inhibin suppression of activin-induced FSH release.","evidence":"Site-directed mutagenesis of inhibin A with binding assay and pituitary cell FSH bioassay","pmids":["18397882"],"confidence":"High","gaps":["No co-crystal structure of inhibin–betaglycan complex","Whether same epitope mediates inhibin B binding unclear"]},{"year":2009,"claim":"In vivo genetic studies established that betaglycan is required for fetal testis development and dose-sensitively controls kidney morphogenesis, while biophysical studies showed that high-affinity TGF-β binding requires both ectodomain lobes tethered together, with plasmin cleavage between them abolishing neutralizing activity. Betaglycan was confirmed as an obligate endogenous inhibin co-receptor in primary gonadotropes.","evidence":"Knockout/heterozygous mice with morphological and molecular phenotyping; plasmin proteolysis with SPR and bioassay; siRNA and neutralizing antibody in primary gonadotropes","pmids":["19696014","21533152","19842711","19372236"],"confidence":"High","gaps":["Embryonic lethality of null mice limits adult phenotype analysis","Whether developmental phenotypes are TGF-β-, inhibin-, or Wnt-dependent unresolved"]},{"year":2010,"claim":"Inhibin A was found to antagonize TGF-β2 signaling by inducing clathrin-independent endocytic internalization of betaglycan, reducing surface TGF-β2 binding sites — a mechanism distinct from TGF-β-induced internalization. The transmembrane-cytoplasmic stub remaining after shedding was identified as a γ-secretase substrate whose accumulation blunts TGF-β2 signaling.","evidence":"Endocytosis inhibitors and binding assays in adrenocortical cells; γ-secretase inhibitors and reporter assays in HepG2 cells","pmids":["20160125","21167215"],"confidence":"Medium","gaps":["Downstream fate of γ-secretase-released intracellular domain unknown","Whether internalized betaglycan is recycled or degraded unclear"]},{"year":2011,"claim":"The crystal structure of the betaglycan ZP-C domain at 2.0 Å revealed an immunoglobulin-like fold with a convex surface pocket important for TGF-β binding, and explained why betaglycan, lacking the ZP maturation cleavage site, does not polymerize like other ZP proteins.","evidence":"X-ray crystallography at 2.0 Å resolution","pmids":["21402931"],"confidence":"High","gaps":["No structure of full ectodomain or ternary ligand–receptor complex","ZP-C–inhibin binding interface not structurally resolved"]},{"year":2013,"claim":"Betaglycan was shown to act as a signaling switch that redirects TGF-β signaling from Smad2/3 toward Smad1/5/8 via ALK1, driving myofibroblast differentiation in lung fibroblasts, with expression upregulated by glucocorticoids.","evidence":"Dexamethasone treatment, siRNA, reporter assays, and in vivo mouse lung experiments","pmids":["24347165"],"confidence":"High","gaps":["Mechanism of ALK1 pathway potentiation by betaglycan unclear","Whether this switch operates in other fibroblast lineages unknown"]},{"year":2014,"claim":"TGFBR3 was found to scaffold a complex with β-arrestin 2 and IκBα to inhibit NF-κB signaling, suppressing EMT and migration in oral cancer cells — a TGF-β-independent signaling mechanism mediated by its cytoplasmic domain.","evidence":"Co-immunoprecipitation, overexpression, β-arrestin 2 siRNA, migration/invasion assays","pmids":["29130787"],"confidence":"Medium","gaps":["Direct binding between TGFBR3 cytoplasmic domain and β-arrestin 2 not demonstrated with purified proteins","Physiological trigger for this complex formation unknown"]},{"year":2016,"claim":"Biophysical studies defined the hand-off mechanism quantitatively: betaglycan binds TGF-β homodimer with 1:1 stoichiometry allowing one TGFBR2 to bind simultaneously, but betaglycan must be displaced for TGFBR1 recruitment. Separately, betaglycan GAG chains were shown to independently regulate Wnt3a signaling, with heparan sulfate and chondroitin sulfate exerting opposing effects.","evidence":"SPR, ITC, and SEC for stoichiometry; GAG mutant constructs with Wnt reporter assays","pmids":["27951653","27784788"],"confidence":"High","gaps":["Whether hand-off occurs on the plasma membrane in real time not visualized","In vivo relevance of GAG-mediated Wnt regulation not tested"]},{"year":2018,"claim":"NMR and mutagenesis mapped the betaglycan ZP-C binding site on TGF-β2 to the inner concave finger region (Ile-92, Lys-97, Glu-99), explaining isoform selectivity for TGF-βs and inhibin A over BMPs. Conditional gonadotrope knockout confirmed TGFBR3 as an inhibin A-specific (not inhibin B) co-receptor in vivo, with knockout females showing super-fertility.","evidence":"NMR titrations, SPR, site-directed mutagenesis; conditional Cre-lox gonadotrope knockout with FSH assays","pmids":["30598510","30364975"],"confidence":"High","gaps":["Full-length betaglycan–TGF-β2 co-structure still lacking at this point","Mechanism of inhibin A vs. inhibin B selectivity at structural level unresolved"]},{"year":2025,"claim":"Cryo-EM structure of TGF-β bound simultaneously to betaglycan and TGFBR1/TGFBR2 provided near-atomic resolution of the hand-off mechanism, revealing how betaglycan engages TGF-β at interfaces distinct from endoglin and is displaced upon signaling receptor assembly.","evidence":"Cryo-EM structural determination with functional validation","pmids":["40011426"],"confidence":"High","gaps":["Structure of betaglycan–inhibin–ActRII ternary complex not yet determined","Role of GAG chains in the structural assembly not visualized"]},{"year":null,"claim":"Key unresolved questions include the structural basis of the inhibin A–betaglycan–ActRII ternary complex, the identity of cytoplasmic domain binding partners mediating p38 MAPK and β-arrestin 2 signaling, the physiological contexts governing whether betaglycan promotes versus inhibits TGF-β signaling, and the in vivo significance of GAG-mediated Wnt regulation.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of inhibin–betaglycan–ActRII complex","Cytoplasmic domain signaling partners not identified by unbiased approaches","Context-dependent switch between positive and negative TGF-β regulation not mechanistically resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,15,17]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,4,6,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,7,8,30]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2,4]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,3,7,9]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,8,12,15,18,33]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[28,29]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[21,28]}],"complexes":["TGF-β–betaglycan–TGFBR2 ternary complex","Inhibin A–betaglycan–ActRII ternary complex","Betaglycan–endoglin complex","Betaglycan–β-arrestin 2–IκBα complex"],"partners":["TGFBR2","TGFBR1","ACVR2A","ENG","ARRB2","INHA","MMP14","GIPC1"],"other_free_text":[]},"mechanistic_narrative":"TGFBR3 (betaglycan) is a membrane-anchored proteoglycan co-receptor that orchestrates TGF-β superfamily signaling by presenting ligands to signaling receptors, sequestering ligands in soluble form, and independently modulating Wnt and NF-κB pathways. Its ectodomain contains two TGF-β-binding lobes — an N-terminal endoglin-related domain that mediates TGF-β presentation to TGFBR2 via a hand-off mechanism requiring betaglycan displacement by TGFBR1, and a C-terminal zona pellucida domain that serves as the obligate inhibin A co-receptor, forming ternary complexes with activin type II receptors to antagonize activin signaling in gonadotropes and other tissues [PMID:8391934, PMID:10746731, PMID:27951653, PMID:40011426, PMID:30364975]. The shed soluble ectodomain acts as a potent TGF-β antagonist with preferential neutralization of TGF-β2, while its glycosaminoglycan chains independently bind bFGF, differentially regulate Wnt3a signaling (heparan sulfate inhibitory, chondroitin sulfate stimulatory), and modulate TGFBR1–TGFBR2 complex formation [PMID:8106553, PMID:11668175, PMID:27784788, PMID:1556106]. Betaglycan also signals in a TGF-β-independent manner through its cytoplasmic domain via p38 MAPK and through β-arrestin 2–mediated NF-κB inhibition, and is required for normal fetal testis development and dose-sensitive kidney morphogenesis [PMID:16413747, PMID:29130787, PMID:19696014, PMID:21533152]."},"prefetch_data":{"uniprot":{"accession":"Q03167","full_name":"Transforming growth factor beta receptor type 3","aliases":["Betaglycan","Transforming growth factor beta receptor III","TGF-beta receptor type III"],"length_aa":851,"mass_kda":93.5,"function":"Cell surface receptor that regulates diverse cellular processes including cell proliferation, differentiation, migration, and apoptosis (PubMed:12958365, PubMed:19416857). Initiates BMP, inhibin, and TGF-beta signaling pathways by interacting with different ligands including TGFB1, BMP2, BMP5, BMP7 or GDF5 (PubMed:18184661). Alternatively, acts as a cell surface coreceptor for BMP ligands, serving to enhance ligand binding by differentially regulating BMPR1A/ALK3 and BMPR1B/ALK6 receptor trafficking (PubMed:19726563). Promotes epithelial cell adhesion, focal adhesion formation and integrin signaling during epithelial cell spreading on fibronectin (PubMed:22562249). By interacting with the scaffolding protein beta-arrestin2/ARRB2, regulates migration or actin cytoskeleton and promotes the activation of CDC42 as well as the inhibition of NF-kappa-B (PubMed:19416857, PubMed:19325136). In gonadotrope cells, acts as an inhibin A coreceptor and regulates follicle-stimulating hormone (FSH) levels and female fertility (By similarity). Plays a role in the inhibition of directed and random cell migration in epithelial cells by altering the actin cytoskeletal organization (PubMed:19416857). Participates in epithelial-mesenchymal transformation (EMT) upon binding to BMP2 or TGFB2, by activating the PAR6/SMURF1/RHOA pathway (By similarity) (Microbial infection) May act as a receptor for human cytomegalovirus in different cell types by interacting with HCMV trimer composed of GO, GH and GL","subcellular_location":"Cell membrane; Secreted; Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q03167/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TGFBR3","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TGFBR3","total_profiled":1310},"omim":[{"mim_id":"612728","title":"BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 14; BMND14","url":"https://www.omim.org/entry/612728"},{"mim_id":"612727","title":"BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 13; BMND13","url":"https://www.omim.org/entry/612727"},{"mim_id":"604383","title":"GROWTH FACTOR-INDEPENDENT 1B; GFI1B","url":"https://www.omim.org/entry/604383"},{"mim_id":"600742","title":"TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE III; TGFBR3","url":"https://www.omim.org/entry/600742"},{"mim_id":"190181","title":"TRANSFORMING GROWTH FACTOR-BETA RECEPTOR, TYPE I; TGFBR1","url":"https://www.omim.org/entry/190181"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TGFBR3"},"hgnc":{"alias_symbol":["betaglycan","BGCAN"],"prev_symbol":[]},"alphafold":{"accession":"Q03167","domains":[{"cath_id":"-","chopping":"46-216","consensus_level":"high","plddt":87.9991,"start":46,"end":216},{"cath_id":"-","chopping":"217-356","consensus_level":"high","plddt":84.1866,"start":217,"end":356},{"cath_id":"2.60.40.3210","chopping":"453-529_566-574","consensus_level":"high","plddt":77.0233,"start":453,"end":574},{"cath_id":"2.60.40.4100","chopping":"592-756","consensus_level":"high","plddt":79.9924,"start":592,"end":756}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03167","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q03167-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q03167-F1-predicted_aligned_error_v6.png","plddt_mean":71.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TGFBR3","jax_strain_url":"https://www.jax.org/strain/search?query=TGFBR3"},"sequence":{"accession":"Q03167","fasta_url":"https://rest.uniprot.org/uniprotkb/Q03167.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q03167/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03167"}},"corpus_meta":[{"pmid":"8391934","id":"PMC_8391934","title":"Betaglycan presents ligand to the TGF beta signaling receptor.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8391934","citation_count":814,"is_preprint":false},{"pmid":"1657406","id":"PMC_1657406","title":"Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system.","date":"1991","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1657406","citation_count":613,"is_preprint":false},{"pmid":"10746731","id":"PMC_10746731","title":"Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.","date":"2000","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10746731","citation_count":476,"is_preprint":false},{"pmid":"8106553","id":"PMC_8106553","title":"Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8106553","citation_count":349,"is_preprint":false},{"pmid":"2592419","id":"PMC_2592419","title":"Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta.","date":"1989","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/2592419","citation_count":334,"is_preprint":false},{"pmid":"31307515","id":"PMC_31307515","title":"Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31307515","citation_count":277,"is_preprint":false},{"pmid":"9830054","id":"PMC_9830054","title":"Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9830054","citation_count":192,"is_preprint":false},{"pmid":"19249006","id":"PMC_19249006","title":"Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19249006","citation_count":155,"is_preprint":false},{"pmid":"11278442","id":"PMC_11278442","title":"Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278442","citation_count":134,"is_preprint":false},{"pmid":"1556106","id":"PMC_1556106","title":"Binding of two growth factor families to separate domains of the proteoglycan betaglycan.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1556106","citation_count":127,"is_preprint":false},{"pmid":"12183427","id":"PMC_12183427","title":"Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12183427","citation_count":124,"is_preprint":false},{"pmid":"11668175","id":"PMC_11668175","title":"Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11668175","citation_count":115,"is_preprint":false},{"pmid":"14672946","id":"PMC_14672946","title":"The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14672946","citation_count":105,"is_preprint":false},{"pmid":"17522389","id":"PMC_17522389","title":"Loss of betaglycan expression in ovarian cancer: role in motility and invasion.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17522389","citation_count":99,"is_preprint":false},{"pmid":"21717526","id":"PMC_21717526","title":"Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21717526","citation_count":99,"is_preprint":false},{"pmid":"22479366","id":"PMC_22479366","title":"Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-β1.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22479366","citation_count":95,"is_preprint":false},{"pmid":"21550381","id":"PMC_21550381","title":"Betaglycan: a multifunctional accessory.","date":"2011","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21550381","citation_count":93,"is_preprint":false},{"pmid":"11912285","id":"PMC_11912285","title":"Expression of activin receptors, follistatin and betaglycan by human endometrial stromal cells; consistent with a role for activins during decidualization.","date":"2002","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/11912285","citation_count":84,"is_preprint":false},{"pmid":"29707897","id":"PMC_29707897","title":"Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3.","date":"2018","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/29707897","citation_count":78,"is_preprint":false},{"pmid":"11256966","id":"PMC_11256966","title":"Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11256966","citation_count":78,"is_preprint":false},{"pmid":"12385827","id":"PMC_12385827","title":"Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors.","date":"2002","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12385827","citation_count":70,"is_preprint":false},{"pmid":"21307088","id":"PMC_21307088","title":"Genome-wide association studies in Asians confirm the involvement of ATOH7 and TGFBR3, and further identify CARD10 as a novel locus influencing optic disc area.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21307088","citation_count":70,"is_preprint":false},{"pmid":"21792916","id":"PMC_21792916","title":"TGFBR3, a potential negative regulator of TGF-β signaling, protects cardiac fibroblasts from hypoxia-induced apoptosis.","date":"2011","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21792916","citation_count":70,"is_preprint":false},{"pmid":"16621788","id":"PMC_16621788","title":"Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16621788","citation_count":69,"is_preprint":false},{"pmid":"10951214","id":"PMC_10951214","title":"Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10951214","citation_count":68,"is_preprint":false},{"pmid":"24658685","id":"PMC_24658685","title":"A time- and matrix-dependent TGFBR3-JUND-KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignancies.","date":"2014","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24658685","citation_count":65,"is_preprint":false},{"pmid":"15468171","id":"PMC_15468171","title":"Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer.","date":"2005","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15468171","citation_count":60,"is_preprint":false},{"pmid":"8226781","id":"PMC_8226781","title":"Localization of transforming growth factor beta binding site in betaglycan. Comparison with small extracellular matrix proteoglycans.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8226781","citation_count":60,"is_preprint":false},{"pmid":"29391598","id":"PMC_29391598","title":"Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29391598","citation_count":59,"is_preprint":false},{"pmid":"24705316","id":"PMC_24705316","title":"TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24705316","citation_count":58,"is_preprint":false},{"pmid":"33307448","id":"PMC_33307448","title":"Regulation of H2S-induced necroptosis and inflammation in broiler bursa of Fabricius by the miR-15b-5p/TGFBR3 axis and the involvement of oxidative stress in this process.","date":"2020","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/33307448","citation_count":58,"is_preprint":false},{"pmid":"11861534","id":"PMC_11861534","title":"The distribution of betaglycan protein and mRNA in rat brain, pituitary, and gonads: implications for a role for betaglycan in inhibin-mediated reproductive functions.","date":"2002","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11861534","citation_count":58,"is_preprint":false},{"pmid":"24347165","id":"PMC_24347165","title":"Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-β signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24347165","citation_count":57,"is_preprint":false},{"pmid":"12052232","id":"PMC_12052232","title":"Expression and localization of inhibin alpha, inhibin/activin betaA and betaB and the activin type II and inhibin beta-glycan receptors in the developing human testis.","date":"2002","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12052232","citation_count":57,"is_preprint":false},{"pmid":"19696014","id":"PMC_19696014","title":"Fetal testis dysgenesis and compromised Leydig cell function in Tgfbr3 (beta glycan) knockout mice.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19696014","citation_count":56,"is_preprint":false},{"pmid":"1744125","id":"PMC_1744125","title":"Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1744125","citation_count":56,"is_preprint":false},{"pmid":"17192875","id":"PMC_17192875","title":"TGFBR3 loss and consequences in prostate cancer.","date":"2007","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/17192875","citation_count":55,"is_preprint":false},{"pmid":"20739376","id":"PMC_20739376","title":"Changes in expression of bone morphogenetic proteins (BMPs), their receptors and inhibin co-receptor betaglycan during bovine antral follicle development: inhibin can antagonize the suppressive effect of BMPs on thecal androgen production.","date":"2010","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20739376","citation_count":55,"is_preprint":false},{"pmid":"31601110","id":"PMC_31601110","title":"Structural biology of betaglycan and endoglin, membrane-bound co-receptors of the TGF-beta family.","date":"2019","source":"Experimental biology and medicine (Maywood, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/31601110","citation_count":51,"is_preprint":false},{"pmid":"35369660","id":"PMC_35369660","title":"Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy.","date":"2021","source":"Kidney360","url":"https://pubmed.ncbi.nlm.nih.gov/35369660","citation_count":49,"is_preprint":false},{"pmid":"1310325","id":"PMC_1310325","title":"Subtypes of betaglycan and of type I and type II transforming growth factor-beta (TGF-beta) receptors with different affinities for TGF-beta 1 and TGF-beta 2 are exhibited by human placental trophoblast cells.","date":"1992","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/1310325","citation_count":49,"is_preprint":false},{"pmid":"16954341","id":"PMC_16954341","title":"Soluble betaglycan reduces renal damage progression in db/db mice.","date":"2006","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16954341","citation_count":48,"is_preprint":false},{"pmid":"19164448","id":"PMC_19164448","title":"Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19164448","citation_count":47,"is_preprint":false},{"pmid":"21402931","id":"PMC_21402931","title":"Structure of betaglycan zona pellucida (ZP)-C domain provides insights into ZP-mediated protein polymerization and TGF-beta binding.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21402931","citation_count":45,"is_preprint":false},{"pmid":"30729664","id":"PMC_30729664","title":"Novel role of the clustered miR-23b-3p and miR-27b-3p in enhanced expression of fibrosis-associated genes by targeting TGFBR3 in atrial fibroblasts.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30729664","citation_count":43,"is_preprint":false},{"pmid":"11818494","id":"PMC_11818494","title":"Inhibin binding protein (InhBP/p120), betaglycan, and the continuing search for the inhibin receptor.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11818494","citation_count":43,"is_preprint":false},{"pmid":"30364975","id":"PMC_30364975","title":"Betaglycan (TGFBR3) Functions as an Inhibin A, but Not Inhibin B, Coreceptor in Pituitary Gonadotrope Cells in Mice.","date":"2018","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30364975","citation_count":43,"is_preprint":false},{"pmid":"14500575","id":"PMC_14500575","title":"Betaglycan localization in the female rat pituitary: implications for the regulation of follicle-stimulating hormone by inhibin.","date":"2003","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/14500575","citation_count":43,"is_preprint":false},{"pmid":"11911962","id":"PMC_11911962","title":"Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan.","date":"2002","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11911962","citation_count":42,"is_preprint":false},{"pmid":"12399463","id":"PMC_12399463","title":"Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation. Cloning of murine betaglycan gene promoter and its modulation by MyoD, retinoic acid, and transforming growth factor-beta.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12399463","citation_count":40,"is_preprint":false},{"pmid":"32491253","id":"PMC_32491253","title":"The STAT3-miR-223-TGFBR3/HMGCS1 axis modulates the progression of cervical carcinoma.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32491253","citation_count":39,"is_preprint":false},{"pmid":"19842711","id":"PMC_19842711","title":"Betaglycan has two independent domains required for high affinity TGF-beta binding: proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19842711","citation_count":39,"is_preprint":false},{"pmid":"8068006","id":"PMC_8068006","title":"Plasmin cleaves betaglycan and releases a 60 kDa transforming growth factor-beta complex from the cell surface.","date":"1994","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8068006","citation_count":39,"is_preprint":false},{"pmid":"27951653","id":"PMC_27951653","title":"Binding Properties of the Transforming Growth Factor-β Coreceptor Betaglycan: Proposed Mechanism for Potentiation of Receptor Complex Assembly and Signaling.","date":"2016","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27951653","citation_count":39,"is_preprint":false},{"pmid":"18397882","id":"PMC_18397882","title":"Suppression of inhibin A biological activity by alterations in the binding site for betaglycan.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18397882","citation_count":39,"is_preprint":false},{"pmid":"16413747","id":"PMC_16413747","title":"Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16413747","citation_count":39,"is_preprint":false},{"pmid":"31401194","id":"PMC_31401194","title":"MicroRNA let-7-TGFBR3 signalling regulates cardiomyocyte apoptosis after infarction.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31401194","citation_count":38,"is_preprint":false},{"pmid":"15745937","id":"PMC_15745937","title":"Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma.","date":"2005","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15745937","citation_count":38,"is_preprint":false},{"pmid":"29130787","id":"PMC_29130787","title":"miR-19a and miR-424 target TGFBR3 to promote epithelial-to-mesenchymal transition and migration of tongue squamous cell carcinoma cells.","date":"2017","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/29130787","citation_count":38,"is_preprint":false},{"pmid":"12568406","id":"PMC_12568406","title":"Endoglin is expressed on human chondrocytes and forms a heteromeric complex with betaglycan in a ligand and type II TGFbeta receptor independent manner.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/12568406","citation_count":38,"is_preprint":false},{"pmid":"19372236","id":"PMC_19372236","title":"Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes.","date":"2009","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19372236","citation_count":38,"is_preprint":false},{"pmid":"18236212","id":"PMC_18236212","title":"Differential expression of TGFBR3 (betaglycan) in mouse ovary and testis during gonadogenesis.","date":"2007","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/18236212","citation_count":37,"is_preprint":false},{"pmid":"20160125","id":"PMC_20160125","title":"Inhibin-A antagonizes TGFbeta2 signaling by down-regulating cell surface expression of the TGFbeta coreceptor betaglycan.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20160125","citation_count":36,"is_preprint":false},{"pmid":"8645162","id":"PMC_8645162","title":"Betaglycan has multiple binding sites for transforming growth factor-beta 1.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8645162","citation_count":36,"is_preprint":false},{"pmid":"25492477","id":"PMC_25492477","title":"Lactoferrin causes IgA and IgG2b isotype switching through betaglycan binding and activation of canonical TGF-β signaling.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25492477","citation_count":35,"is_preprint":false},{"pmid":"37794449","id":"PMC_37794449","title":"Exosome-derived circ_0001785 delays atherogenesis through the ceRNA network mechanism of miR-513a-5p/TGFBR3.","date":"2023","source":"Journal of nanobiotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37794449","citation_count":34,"is_preprint":false},{"pmid":"31525642","id":"PMC_31525642","title":"Hsa_circ_0042666 inhibits proliferation and invasion via regulating miR-223/TGFBR3 axis in laryngeal squamous cell carcinoma.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31525642","citation_count":33,"is_preprint":false},{"pmid":"12456797","id":"PMC_12456797","title":"Transforming growth factor-beta modulates inhibin A bioactivity in the LbetaT2 gonadotrope cell line by competing for binding to betaglycan.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12456797","citation_count":32,"is_preprint":false},{"pmid":"17845732","id":"PMC_17845732","title":"Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells.","date":"2007","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17845732","citation_count":30,"is_preprint":false},{"pmid":"34129838","id":"PMC_34129838","title":"Inhibiting microRNA-424 in bone marrow mesenchymal stem cells-derived exosomes suppresses tumor growth in colorectal cancer by upregulating TGFBR3.","date":"2021","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/34129838","citation_count":30,"is_preprint":false},{"pmid":"11451571","id":"PMC_11451571","title":"Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan-glycan.","date":"2001","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11451571","citation_count":29,"is_preprint":false},{"pmid":"30467960","id":"PMC_30467960","title":"MicroRNA let-7a regulates angiogenesis by targeting TGFBR3 mRNA.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30467960","citation_count":29,"is_preprint":false},{"pmid":"7559813","id":"PMC_7559813","title":"Serglycin and betaglycan proteoglycans are expressed in the megakaryocytic cell line CHRF 288-11 and normal human megakaryocytes.","date":"1995","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7559813","citation_count":29,"is_preprint":false},{"pmid":"33280236","id":"PMC_33280236","title":"HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3.","date":"2020","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33280236","citation_count":28,"is_preprint":false},{"pmid":"17656464","id":"PMC_17656464","title":"Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan.","date":"2007","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17656464","citation_count":28,"is_preprint":false},{"pmid":"31409900","id":"PMC_31409900","title":"Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31409900","citation_count":27,"is_preprint":false},{"pmid":"30382077","id":"PMC_30382077","title":"Plau and Tgfbr3 are YAP-regulated genes that promote keratinocyte proliferation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30382077","citation_count":27,"is_preprint":false},{"pmid":"21533152","id":"PMC_21533152","title":"Betaglycan is required for the establishment of nephron endowment in the mouse.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21533152","citation_count":27,"is_preprint":false},{"pmid":"36897738","id":"PMC_36897738","title":"Exosomal miR-103a-3p from Crohn's Creeping Fat-Derived Adipose-Derived Stem Cells Contributes to Intestinal Fibrosis by Targeting TGFBR3 and Activating Fibroblasts.","date":"2023","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/36897738","citation_count":26,"is_preprint":false},{"pmid":"14557487","id":"PMC_14557487","title":"Expression of betaglycan, an inhibin coreceptor, in normal human ovaries and ovarian sex cord-stromal tumors and its regulation in cultured human granulosa-luteal cells.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14557487","citation_count":26,"is_preprint":false},{"pmid":"23322721","id":"PMC_23322721","title":"Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.","date":"2013","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/23322721","citation_count":24,"is_preprint":false},{"pmid":"27784788","id":"PMC_27784788","title":"Altering the Proteoglycan State of Transforming Growth Factor β Type III Receptor (TβRIII)/Betaglycan Modulates Canonical Wnt/β-Catenin Signaling.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27784788","citation_count":23,"is_preprint":false},{"pmid":"32471132","id":"PMC_32471132","title":"The Tumor Suppressor TGFBR3 Blocks Lymph Node Metastasis in Head and Neck Cancer.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32471132","citation_count":22,"is_preprint":false},{"pmid":"16613887","id":"PMC_16613887","title":"Mutational analysis of the betaglycan gene-coding region in susceptibility for ovarian failure.","date":"2006","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16613887","citation_count":22,"is_preprint":false},{"pmid":"10384983","id":"PMC_10384983","title":"A regulatory role of fibroblast growth factor in the expression of decorin, biglycan, betaglycan and syndecan in osteoblasts from patients with Crouzon's syndrome.","date":"1999","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10384983","citation_count":22,"is_preprint":false},{"pmid":"21167215","id":"PMC_21167215","title":"The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease γ-secretase.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21167215","citation_count":22,"is_preprint":false},{"pmid":"36180862","id":"PMC_36180862","title":"LncRNA H19 alleviates sepsis-induced acute lung injury by regulating the miR-107/TGFBR3 axis.","date":"2022","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36180862","citation_count":21,"is_preprint":false},{"pmid":"37941530","id":"PMC_37941530","title":"Exosomes Derived from E2F1-/- Adipose-Derived Stem Cells Promote Skin Wound Healing via miR-130b-5p/TGFBR3 Axis.","date":"2023","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37941530","citation_count":21,"is_preprint":false},{"pmid":"35310542","id":"PMC_35310542","title":"Promoter Hypomethylation of TGFBR3 as a Risk Factor of Alzheimer's Disease: An Integrated Epigenomic-Transcriptomic Analysis.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35310542","citation_count":20,"is_preprint":false},{"pmid":"38438372","id":"PMC_38438372","title":"Cancer associated fibroblasts-derived SULF1 promotes gastric cancer metastasis and CDDP resistance through the TGFBR3-mediated TGF-β signaling pathway.","date":"2024","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38438372","citation_count":20,"is_preprint":false},{"pmid":"39092729","id":"PMC_39092729","title":"The Role of TGFBR3 in the Development of Lung Cancer.","date":"2024","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/39092729","citation_count":19,"is_preprint":false},{"pmid":"40011426","id":"PMC_40011426","title":"Structures of TGF-β with betaglycan and signaling receptors reveal mechanisms of complex assembly and signaling.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40011426","citation_count":19,"is_preprint":false},{"pmid":"31648935","id":"PMC_31648935","title":"A Tale of Two Proteins: Betaglycan, IGSF1, and the Continuing Search for the Inhibin B Receptor.","date":"2019","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/31648935","citation_count":19,"is_preprint":false},{"pmid":"26277894","id":"PMC_26277894","title":"Retinoic acid enhances lactoferrin-induced IgA responses by increasing betaglycan expression.","date":"2015","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26277894","citation_count":19,"is_preprint":false},{"pmid":"30598510","id":"PMC_30598510","title":"TGF-β2 uses the concave surface of its extended finger region to bind betaglycan's ZP domain via three residues specific to TGF-β and inhibin-α.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30598510","citation_count":19,"is_preprint":false},{"pmid":"25128652","id":"PMC_25128652","title":"Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25128652","citation_count":18,"is_preprint":false},{"pmid":"34162229","id":"PMC_34162229","title":"Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome.","date":"2021","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34162229","citation_count":18,"is_preprint":false},{"pmid":"29979612","id":"PMC_29979612","title":"The t(1;10)(p22;q24) TGFBR3/MGEA5 Translocation in Pleomorphic Hyalinizing Angiectatic Tumor, Myxoinflammatory Fibroblastic Sarcoma, and Hemosiderotic Fibrolipomatous Tumor.","date":"2018","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29979612","citation_count":18,"is_preprint":false},{"pmid":"20813352","id":"PMC_20813352","title":"Synthesis of the glycosaminoglycan-protein linkage tetraosyl peptide moieties of betaglycan, which serve as a hexosamine acceptor for enzymatic glycosyl transfer.","date":"2010","source":"Carbohydrate research","url":"https://pubmed.ncbi.nlm.nih.gov/20813352","citation_count":18,"is_preprint":false},{"pmid":"19524135","id":"PMC_19524135","title":"Reducing betaglycan expression by RNA interference (RNAi) attenuates inhibin bioactivity in LbetaT2 gonadotropes.","date":"2009","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19524135","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54369,"output_tokens":9502,"usd":0.152818},"stage2":{"model":"claude-opus-4-6","input_tokens":13872,"output_tokens":5048,"usd":0.29334},"total_usd":0.446158,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Betaglycan (TGFBR3) presents TGF-β directly to the type II signaling receptor kinase, forming a high-affinity ternary complex. Membrane betaglycan increases TGF-β binding to the signaling receptor, enhances cell responsiveness to TGF-β, and eliminates biological differences between TGF-β isoforms.\",\n      \"method\": \"Affinity labeling, cross-linking, cell-based binding assays, bioassays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — foundational study with multiple orthogonal methods, >800 citations, replicated extensively\",\n      \"pmids\": [\"8391934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Betaglycan is a membrane-anchored proteoglycan with an extracellular domain carrying glycosaminoglycan chains; its ectodomain can be shed as a soluble proteoglycan. The transmembrane and cytoplasmic regions share homology with endoglin. GAG chains are dispensable for TGF-β binding to the core protein.\",\n      \"method\": \"cDNA cloning, structural analysis, biochemical characterization\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — primary structure determination with functional domain analysis, >600 citations\",\n      \"pmids\": [\"1657406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Betaglycan exists in both membrane-bound and soluble forms; the membrane form is hydrophobic and associates with liposomes, while soluble forms lack a membrane anchor. Both bind TGF-β via the core protein and carry heparan sulfate and/or chondroitin sulfate GAG chains.\",\n      \"method\": \"Affinity labeling, liposome association assay, biochemical fractionation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original identification with multiple biochemical methods, >330 citations\",\n      \"pmids\": [\"2592419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"TGF-β binds to the NH2-terminal endoglin-related region of betaglycan. GAG attachment sites are Ser535 and Ser546 in the uromodulin-related region; their mutation prevents GAG attachment but does not affect TGF-β binding or presentation. Soluble betaglycan (lacking membrane anchor) cannot present TGF-β to the type II receptor and instead acts as a potent inhibitor of TGF-β, particularly the TGF-β2 isoform.\",\n      \"method\": \"Site-directed mutagenesis, deletion mutagenesis, cell-based binding assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional readouts, >340 citations\",\n      \"pmids\": [\"8106553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Betaglycan functions as an inhibin co-receptor with ActRII. Betaglycan binds inhibin with high affinity, enhances inhibin binding in cells co-expressing ActRII and betaglycan, and inhibin forms crosslinked complexes with both betaglycan and ActRII. Betaglycan confers inhibin sensitivity to cell lines that otherwise respond poorly, mediating functional antagonism of activin signaling.\",\n      \"method\": \"Receptor binding assays, cross-linking, co-expression, functional antagonism assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, >470 citations, replicated by multiple labs\",\n      \"pmids\": [\"10746731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Betaglycan binds bFGF via its heparan sulfate chains (separate from the TGF-β binding core protein domain). bFGF treatment of osteoblasts selectively reduces heparan sulfate GAG content of betaglycan without affecting chondroitin sulfate or core protein, demonstrating ligand-regulated remodeling of the bFGF-binding domain.\",\n      \"method\": \"Affinity labeling, GAG composition analysis, cell-based ligand binding\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods demonstrating dual-ligand binding at distinct domains, >125 citations\",\n      \"pmids\": [\"1556106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Betaglycan ectodomain contains two independent TGF-β binding domains: the NH2-terminal endoglin-related region and the COOH-terminal uromodulin-related region. Only the endoglin-related region mediates TGF-β presentation to TGF-β type II receptor. The uromodulin-related region specifically binds inhibin A with relative affinities TGF-β2 > inhibin A > TGF-β1.\",\n      \"method\": \"Deletion mutagenesis, ligand binding competition, Smad2 phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — domain mutagenesis with multiple functional readouts\",\n      \"pmids\": [\"11278442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Recombinant soluble betaglycan is a homodimer (two 110 kDa monomers, non-covalent) lacking GAG chains. It binds TGF-β isoforms with relative affinities TGF-β2 > TGF-β3 > TGF-β1, with Kd ~3.5 nM for TGF-β1, and neutralizes TGF-β activity with 10-fold higher potency against TGF-β2 than TGF-β1.\",\n      \"method\": \"Baculovirus expression, biochemical characterization, bioassay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted recombinant protein with quantitative binding and functional data\",\n      \"pmids\": [\"11256966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In LLC-PK1 renal epithelial cells (which lack endogenous betaglycan), expressed betaglycan inhibits TGF-β signaling by preventing type I–type II receptor complex formation, not by ligand sequestration. This inhibitory effect is mediated by the glycosaminoglycan modifications; a GAG-deficient betaglycan mutant does not inhibit signaling or receptor association.\",\n      \"method\": \"Reporter gene assay, thymidine incorporation, Smad2/3 phosphorylation, co-immunoprecipitation of receptor complexes, GAG mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple functional readouts, mutagenesis, mechanistically distinct finding\",\n      \"pmids\": [\"11668175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Betaglycan shedding (release of the soluble ectodomain) is induced by pervanadate (a tyrosine phosphatase inhibitor) and generates a 90 kDa fragment (sBG-90) whose production is mediated by MT1-MMP (membrane type-1 matrix metalloprotease). MT3-MMP can also generate this fragment. The released sBG-90 retains preferential binding to TGF-β2 over TGF-β1.\",\n      \"method\": \"Overexpression of MT-MMPs in COS-1 cells, metalloprotease inhibitors, binding competition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic identification of shedding protease with overexpression and inhibitor experiments\",\n      \"pmids\": [\"14672946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A fragment of betaglycan ectodomain (amino acids 543–769) near the transmembrane domain binds TGF-β and at low concentrations enhances TGF-β binding to the type II receptor. The same site is competed by decorin, biglycan, and fibromodulin, indicating overlapping binding interfaces in TGF-β.\",\n      \"method\": \"Recombinant fusion protein expression, competition binding assay, affinity cross-linking, bioassay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — recombinant domain mapping with quantitative binding and functional data\",\n      \"pmids\": [\"8226781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Betaglycan domain spanning amino acids 591–700 (within the ZP domain) is the only inhibin-binding region. The inhibin and TGF-β binding residues overlap; Val614Tyr mutation abolishes inhibin binding but retains TGF-β binding via the N-terminal site. Betaglycan V614Y mutants fail to mediate inhibin antagonism of activin signaling but can still present TGF-β to TβRII, functionally separating the two co-receptor activities.\",\n      \"method\": \"Deletion and point mutagenesis, ligand binding assays, functional antagonism reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — point mutagenesis with functional separation of two activities\",\n      \"pmids\": [\"16621788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Betaglycan can signal in a TGF-β ligand-independent manner through activation of the p38 MAPK pathway, requiring its cytoplasmic domain. This effect increases TGF-β target gene expression (fibronectin, CTGF) and inhibits myogenin in myoblasts independently of Smad2 phosphorylation.\",\n      \"method\": \"Adenoviral overexpression, reporter assays, TGF-β blocking antibodies, p38 inhibitor, cytoplasmic domain mutant\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple reporter/inhibitor experiments in single lab\",\n      \"pmids\": [\"16413747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Betaglycan ectodomain has a bilobular structure; each lobe folds independently and binds TGF-β through distinct non-overlapping interfaces. High-affinity TGF-β binding (Kd low nanomolar) requires both domains tethered together; individual domains bind 1–2 orders of magnitude more weakly. Plasmin cleaves betaglycan between the two domains, separating them and abolishing neutralizing activity.\",\n      \"method\": \"Plasmin proteolysis, N-terminal sequencing, surface plasmon resonance, TGF-β activity bioassay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted fragments with SPR quantitation and functional assays\",\n      \"pmids\": [\"19842711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Crystal structure of the betaglycan ZP-C domain (2.0 Å resolution) reveals an immunoglobulin-like fold. The external hydrophobic patch is integral to ZP-C (corresponds to ZP-C G strand). The AB loop and convex surface pocket are important for TGF-β ligand binding. Absence of the maturation cleavage site (present in polymerizing ZP proteins) explains why betaglycan does not polymerize.\",\n      \"method\": \"X-ray crystallography at 2.0 Å resolution\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with structural-functional interpretation\",\n      \"pmids\": [\"21402931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Betaglycan binds TGF-β homodimers with 1:1 stoichiometry allowing one TβRII to bind simultaneously. Betaglycan modestly potentiates TβRII binding to TGF-β2 but must be displaced for TβRI to bind. This defines a hand-off mechanism: betaglycan concentrates TGF-β2 on the cell surface, promotes TβRII binding by membrane-localization and allostery, and is subsequently displaced by TβRI recruitment.\",\n      \"method\": \"Surface plasmon resonance, isothermal titration calorimetry, size-exclusion chromatography\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical methods defining stoichiometry and mechanism\",\n      \"pmids\": [\"27951653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NMR titrations and SPR identified the BGZP-C binding site on TGF-β2 as the inner concave surface of its extended finger region, involving residues Ile-92, Lys-97, and Glu-99 specific to TGF-β isoforms and inhibin-α. Mutation of these residues to the BMP-2 equivalents reduces BGZP-C binding, explaining betaglycan selectivity for TGF-βs and inhibin A over BMPs.\",\n      \"method\": \"NMR (methyl-labeled TGF-β2), surface plasmon resonance, site-directed mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural mapping with mutagenesis and SPR validation\",\n      \"pmids\": [\"30598510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Cryo-EM/structural determination of TGF-β bound simultaneously to betaglycan and the signaling receptors TGFBR1 and TGFBR2 reveals key ligand engagement interfaces distinct from those of endoglin. The structure explains the hand-off mechanism: betaglycan binds TGF-β, facilitates signaling receptor assembly, then is displaced as signaling receptors engage.\",\n      \"method\": \"Cryo-EM/structural biology with functional validation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — near-atomic structure of complete receptor complex explaining mechanism\",\n      \"pmids\": [\"40011426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Glucocorticoids (dexamethasone) upregulate Tgfbr3 expression in lung fibroblasts, and Tgfbr3 functions as a signaling switch that blunts Tgfbr1/Smad2/3 signaling while potentiating Acvrl1/Smad1/5/8 signaling, driving TGF-β-dependent myofibroblast differentiation (smooth muscle actin and myosin acquisition) in a Smad1-dependent manner.\",\n      \"method\": \"Dexamethasone treatment, siRNA knockdown, reporter assays, in vivo mouse lung experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including in vivo validation\",\n      \"pmids\": [\"24347165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Inhibin-A antagonizes TGFβ2 signaling by inducing clathrin-independent endocytic internalization of betaglycan, reducing available cell-surface betaglycan binding sites for TGFβ2. This is distinct from TGFβ-induced betaglycan internalization and depends on mutual affinity of inhibin-A and TGFβ2 for betaglycan.\",\n      \"method\": \"Cell-surface binding assay, endocytosis inhibitors, functional signaling assays in adrenocortical cells\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistically novel finding with pharmacological and functional evidence in single lab\",\n      \"pmids\": [\"20160125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Betaglycan is an endogenous obligate co-receptor for high-potency inhibin antagonism of activin signaling in rat anterior pituitary gonadotropes. RNAi knockdown and immunoneutralization of betaglycan each independently reduce the potency of inhibin-A antagonism of activin-induced FSH secretion by >1000-fold.\",\n      \"method\": \"siRNA knockdown, neutralizing antibody, primary gonadotrope cultures, FSH secretion assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent loss-of-function approaches with quantitative FSH secretion readout\",\n      \"pmids\": [\"19372236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Conditional knockout of Tgfbr3 specifically in murine gonadotropes impairs inhibin A (but not inhibin B) suppression of FSH synthesis in cultured pituitaries, demonstrating that TGFBR3 is an inhibin A-specific co-receptor in vivo in gonadotropes. Conditional knockout females are super-fertile with enhanced folliculogenesis.\",\n      \"method\": \"Conditional knockout mouse model (gonadotrope-specific Cre), FSH secretion assay, pituitary culture\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean conditional KO with specific isoform-selective phenotypic readout\",\n      \"pmids\": [\"30364975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Plasmin selectively cleaves betaglycan on intact cells, releasing a 60 kDa TGF-β-betaglycan complex into the medium. The type I and type II TGF-β receptors are not plasmin substrates. Plasmin-treated cells release more active TGF-β, indicating betaglycan cleavage liberates active growth factor.\",\n      \"method\": \"Affinity labeling, SDS-PAGE of cell surface receptors, TGF-β bioassay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protease substrate identification with functional consequence\",\n      \"pmids\": [\"8068006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Granzyme B cleaves soluble betaglycan (along with decorin and biglycan) and releases active TGF-β1 from these proteoglycans. The released TGF-β1 retains activity, inducing SMAD-3 phosphorylation in human coronary artery smooth muscle cells.\",\n      \"method\": \"In vitro cleavage assay, cytokine release assay, SMAD3 phosphorylation, granzyme B inhibitor\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro reconstitution with functional signaling readout\",\n      \"pmids\": [\"22479366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"On human microvascular endothelial cells, endoglin associates with betaglycan in a complex that can form in a ligand-dependent or ligand-independent manner. Three higher-order complexes containing endoglin with type I and/or type II TGF-β receptors are also present.\",\n      \"method\": \"Co-immunoprecipitation, affinity labeling with radiolabeled TGF-β\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — co-IP and affinity labeling demonstrating complex formation\",\n      \"pmids\": [\"10951214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"On human chondrocytes, endoglin forms a heteromeric complex with betaglycan in both a ligand-independent and ligand-dependent manner, independent of the type II TGF-β receptor, as shown by co-immunoprecipitation at endogenous receptor concentrations.\",\n      \"method\": \"Co-immunoprecipitation, affinity labeling with radiolabeled TGF-β\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — reciprocal co-IP demonstrating endogenous complex\",\n      \"pmids\": [\"12568406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Betaglycan overexpression in rat myoblasts enhances TGF-β inhibition of proliferation and PAI-1 synthesis, and specifically increases TGF-β binding to the type II receptor (~3.5-fold). Endoglin overexpression has weaker and distinct effects (increases binding to both type I and II receptors). The differential effects reside in the extracellular domain, shown by chimeric protein analysis.\",\n      \"method\": \"Overexpression, 125I-TGF-β affinity cross-linking, proliferation assay, chimeric protein analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct comparison using chimeric receptors with quantitative binding and functional data\",\n      \"pmids\": [\"9830054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Betaglycan's transmembrane-cytoplasmic fragment remaining after ectodomain shedding is stable in cells and is a substrate of γ-secretase. γ-Secretase inhibition or expression of the transmembrane-cytoplasmic fragment blunts TGF-β2 signaling in HepG2 cells.\",\n      \"method\": \"γ-Secretase inhibitors, shedding inhibitor TAPI-2, transfection, TGF-β signaling reporter\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological identification of γ-secretase cleavage with functional consequence\",\n      \"pmids\": [\"21167215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Tgfbr3 (betaglycan) knockout mice show defective seminiferous cord formation, reduced fetal Leydig cell function (decreased Insl3, Cyp17a1, Cyp11a1, Star, Hsd3b1 expression), and reduced Sertoli cell markers (Dhh, Sox9, Amh) without changes in Leydig cell number, indicating betaglycan is required for normal fetal testis structure and endocrine function.\",\n      \"method\": \"Knockout mouse model, immunohistochemistry, quantitative RT-PCR, whole-mount in situ hybridization, morphometry\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean null KO with multiple molecular and morphological phenotypic readouts\",\n      \"pmids\": [\"19696014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Betaglycan heterozygous knockout mice have augmented nephron number and accelerated ureteric branching, while null mice show renal hypoplasia and reduced nephron number. Opposing molecular phenotypes involve altered expression of Bmp4, Pax2, Gdnf, Ret, Wnt4 and other metanephric regulatory genes, demonstrating dose-sensitive betaglycan requirement for kidney development.\",\n      \"method\": \"Knockout and heterozygous mouse models, stereological nephron counting, quantitative RT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — both null and heterozygous models with quantitative morphological and molecular phenotyping\",\n      \"pmids\": [\"21533152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TGFBR3/betaglycan, independent of its TGF-β co-receptor function, regulates canonical Wnt3a signaling through its GAG chains: heparan sulfate chains sequester Wnt3a and inhibit Wnt signaling, while chondroitin sulfate chains promote Wnt3a signaling. The two GAG modifications have opposing effects on Wnt availability.\",\n      \"method\": \"GAG mutant constructs, Wnt reporter assays, ligand binding experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel TGF-β-independent function demonstrated with GAG mutants and functional reporters\",\n      \"pmids\": [\"27784788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The inhibin A binding site on betaglycan maps to an epitope on the outer convex surface of the inhibin α-subunit (residues Val108–Tyr120). Simultaneous substitution of Thr111, Ser112, and Tyr120 to alanine abolishes betaglycan binding and prevents inhibin A suppression of activin-induced FSH release from rat pituitary cells.\",\n      \"method\": \"Site-directed mutagenesis of inhibin A, binding assay, pituitary cell bioassay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis identifying binding epitope validated by functional FSH assay\",\n      \"pmids\": [\"18397882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss of betaglycan expression in ovarian cancer cells is partly due to epigenetic silencing (reversed by 5-aza-2'-deoxycytidine and trichostatin A combination). Restoring betaglycan in Ovca429 cells inhibits cancer cell motility and invasiveness, and enhances antimigratory effects of inhibin and inhibin-mediated repression of MMP levels.\",\n      \"method\": \"Epigenetic drug treatment, stable transfection, motility/invasion assays, MMP measurement\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — restoration-of-function with defined cellular phenotypes\",\n      \"pmids\": [\"17522389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TGFBR3 forms a complex with β-arrestin 2 scaffolding protein and IκBα. Overexpression of TGFBR3 decreases p-p65 and increases IκBα expression, inhibiting NF-κB signaling; this effect is abolished by β-arrestin 2 knockdown. This pathway inhibits EMT and migration in oral squamous cell carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, siRNA knockdown, migration/invasion assays\",\n      \"journal\": \"Cell adhesion & migration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP identifying complex, functional epistasis by β-arrestin knockdown\",\n      \"pmids\": [\"29130787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TGFBR3 induces secretion of angiogenin (ANG), and ANG is required and sufficient to mediate TGFBR3-dependent inhibition of migration and invasion in SMAD4-positive oral cancer cells. In SMAD4-deficient cells, TGFBR3 suppression requires GIPC1 (but not ARRB2), indicating SMAD4-dependent and -independent mechanisms.\",\n      \"method\": \"Overexpression, KD of ARRB2/GIPC1, migration/invasion assays, SMAD4-null cell comparison\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple loss-of-function experiments identifying SMAD4-dependent and independent pathways\",\n      \"pmids\": [\"32471132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of TGFBR3 in clear-cell renal cell carcinoma increases ALDH-positive cancer-initiating cell populations (TGF-β-dependent), and independently enhances cell migration via FAK-PI3K signaling with increased lamellipodium formation, demonstrating TGF-β-dependent and TGF-β-independent metastatic mechanisms of TGFBR3.\",\n      \"method\": \"Orthotopic inoculation in mice, ALDH flow cytometry, FAK-PI3K inhibitors, migration assay, stable KD\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro assays with pathway-specific inhibitors\",\n      \"pmids\": [\"29391598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Lactoferrin directly interacts with betaglycan (TGFBR3) and induces formation of the TGFBR3/TβRII/TβRI complex, leading to Smad3 phosphorylation and IgA isotype switching in B cells. Retinoic acid further augments this by increasing betaglycan expression.\",\n      \"method\": \"Direct binding assay, co-immunoprecipitation of receptor complex, Smad3 phosphorylation, IgA reporter assay, in vivo peroral administration\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding and receptor complex assembly with functional IgA readout\",\n      \"pmids\": [\"25492477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Betaglycan loss in mesenchymal stromal cells augments TGF-β signaling, proliferation, and migration, and completely blocks osteoblast differentiation. Betaglycan controls expression of Wnt5a (>60-fold increase upon loss), which activates canonical Wnt signaling to impair osteogenesis. A Wnt5a neutralizing antibody rescues osteogenic gene expression in betaglycan-ablated MSCs.\",\n      \"method\": \"siRNA knockdown, recombinant Wnt5a addition, neutralizing antibody, osteogenic differentiation assay, in vivo xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with mechanistic rescue by neutralizing antibody and in vivo validation\",\n      \"pmids\": [\"31409900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TGFBR3 is identified as a target of let-7 microRNA. Induction of Tgfbr3 in cardiomyocytes causes apoptosis through p38 MAPK activation. In vivo AAV9-mediated let-7 knockdown exacerbates cardiomyocyte apoptosis after myocardial infarction, while let-7 overexpression reduces it.\",\n      \"method\": \"AAV9-mediated microRNA overexpression/knockdown in mice, apoptosis assays, p38 MAPK measurement\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo AAV experiment linking TGFBR3 to p38 MAPK apoptosis pathway\",\n      \"pmids\": [\"31401194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TGF-β competes with inhibin A for binding to betaglycan on gonadotrope LβT2 cells, thereby reversing inhibin A antagonism of activin-induced FSHβ and GnRHR promoter activity. Immunoprecipitation confirmed TGF-β1 and TGF-β2 compete with inhibin A for betaglycan binding.\",\n      \"method\": \"Radiolabeled inhibin A competition binding, co-immunoprecipitation of receptor complexes, luciferase reporter assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct competition binding and functional reporter data\",\n      \"pmids\": [\"12456797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Betaglycan promoter is regulated by MyoD (but not myogenin) and retinoic acid (upregulation) and by TGF-β isoforms (downregulation). Betaglycan expression is upregulated during C2C12 myoblast-to-myotube differentiation, and forced betaglycan expression increases TGF-β2 responsiveness in myoblasts.\",\n      \"method\": \"Northern/Western blot during differentiation, promoter cloning and reporter assay, transcription factor overexpression, affinity labeling, immunofluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter characterization with multiple transcription factor experiments and functional validation\",\n      \"pmids\": [\"12399463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TGFBR3 overexpression in cardiac fibroblasts prevents hypoxia-induced apoptosis by attenuating TGF-β1/p-Smad2/3 signaling, blocking TGFBR1-TGFBR2 complex formation, reversing Bax upregulation and Bcl-2 downregulation, and inhibiting hypoxia-induced calcium influx.\",\n      \"method\": \"Overexpression, MTT assay, TUNEL, co-immunoprecipitation of receptor complex, calcium imaging\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression with multiple mechanistic readouts including receptor complex IP\",\n      \"pmids\": [\"21792916\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TGFBR3 (betaglycan) is a membrane-anchored proteoglycan co-receptor that presents TGF-β (particularly TGF-β2) to the type II signaling receptor by forming a ternary complex, potentiating receptor assembly; its shed soluble ectodomain acts as a TGF-β antagonist; it functions as an obligate inhibin A co-receptor by binding inhibin A via its ZP (uromodulin-related) domain and facilitating ternary complex formation with activin type II receptors to antagonize activin signaling; the GAG chains mediate bFGF binding and can independently regulate Wnt signaling and TβRI/TβRII complex formation; γ-secretase processes the remaining transmembrane fragment after shedding; and betaglycan can signal in a TGF-β-independent manner through p38 MAPK via its cytoplasmic domain.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TGFBR3 (betaglycan) is a membrane-anchored proteoglycan co-receptor that orchestrates TGF-β superfamily signaling by presenting ligands to signaling receptors, sequestering ligands in soluble form, and independently modulating Wnt and NF-κB pathways. Its ectodomain contains two TGF-β-binding lobes — an N-terminal endoglin-related domain that mediates TGF-β presentation to TGFBR2 via a hand-off mechanism requiring betaglycan displacement by TGFBR1, and a C-terminal zona pellucida domain that serves as the obligate inhibin A co-receptor, forming ternary complexes with activin type II receptors to antagonize activin signaling in gonadotropes and other tissues [PMID:8391934, PMID:10746731, PMID:27951653, PMID:40011426, PMID:30364975]. The shed soluble ectodomain acts as a potent TGF-β antagonist with preferential neutralization of TGF-β2, while its glycosaminoglycan chains independently bind bFGF, differentially regulate Wnt3a signaling (heparan sulfate inhibitory, chondroitin sulfate stimulatory), and modulate TGFBR1–TGFBR2 complex formation [PMID:8106553, PMID:11668175, PMID:27784788, PMID:1556106]. Betaglycan also signals in a TGF-β-independent manner through its cytoplasmic domain via p38 MAPK and through β-arrestin 2–mediated NF-κB inhibition, and is required for normal fetal testis development and dose-sensitive kidney morphogenesis [PMID:16413747, PMID:29130787, PMID:19696014, PMID:21533152].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Before the molecular identity of the type III TGF-β receptor was known, this study established that betaglycan exists as both membrane-bound and soluble proteoglycan forms that bind TGF-β via core protein carrying heparan sulfate and chondroitin sulfate GAG chains.\",\n      \"evidence\": \"Affinity labeling, liposome association, and biochemical fractionation of cell-derived betaglycan\",\n      \"pmids\": [\"2592419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular cloning not yet achieved\", \"Functional role of GAG chains unknown\", \"Mechanism of soluble form generation undefined\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"cDNA cloning revealed betaglycan as a transmembrane proteoglycan with an ectodomain carrying GAG chains and a cytoplasmic domain homologous to endoglin, establishing that GAG chains are dispensable for TGF-β binding to the core protein.\",\n      \"evidence\": \"cDNA cloning, structural domain analysis, biochemical characterization\",\n      \"pmids\": [\"1657406\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Function of cytoplasmic domain unknown\", \"Mechanism of TGF-β presentation not yet demonstrated\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Discovery that betaglycan binds bFGF through its heparan sulfate chains at a site distinct from the TGF-β-binding core protein established betaglycan as a dual-ligand co-receptor with ligand-regulated GAG remodeling.\",\n      \"evidence\": \"Affinity labeling and GAG composition analysis in osteoblasts\",\n      \"pmids\": [\"1556106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of bFGF–betaglycan interaction for FGF signaling unclear\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"The central co-receptor mechanism was established: membrane betaglycan directly presents TGF-β to the type II signaling receptor in a ternary complex, enhancing cell responsiveness and equalizing isoform-specific differences, while a recombinant ectodomain fragment could enhance TGF-β binding to TGFBR2 at low concentrations.\",\n      \"evidence\": \"Affinity labeling, cross-linking, cell-based binding, and bioassays; recombinant fragment competition binding\",\n      \"pmids\": [\"8391934\", \"8226781\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of ternary complex unknown\", \"Mechanism of TGF-β handoff to signaling receptors undefined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Domain mapping showed TGF-β binds the N-terminal endoglin-related region; GAG attachment sites were identified at Ser535/Ser546 in the uromodulin-related region. Critically, soluble betaglycan cannot present TGF-β and instead acts as a potent inhibitor, particularly of TGF-β2, establishing soluble betaglycan as a natural antagonist.\",\n      \"evidence\": \"Site-directed and deletion mutagenesis with cell-based binding and functional assays; plasmin cleavage releasing TGF-β–betaglycan complexes from cells\",\n      \"pmids\": [\"8106553\", \"8068006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease(s) mediating physiological shedding not identified\", \"In vivo antagonist function of soluble betaglycan unconfirmed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"A second major co-receptor function was discovered: betaglycan binds inhibin A with high affinity and, together with ActRII, confers inhibin sensitivity to cells, mediating functional antagonism of activin signaling — establishing betaglycan as a bifunctional co-receptor for both TGF-β and inhibin.\",\n      \"evidence\": \"Receptor binding assays, cross-linking, co-expression, and functional antagonism assays; co-IP showing endoglin–betaglycan complex on endothelial cells\",\n      \"pmids\": [\"10746731\", \"10951214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibin binding domain on betaglycan not mapped\", \"Whether inhibin and TGF-β compete for betaglycan unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The ectodomain was shown to contain two independent TGF-β-binding domains — the N-terminal endoglin-related region mediating presentation to TGFBR2 and the C-terminal uromodulin-related region binding both TGF-β2 and inhibin A. Separately, GAG chains were found to inhibit TGF-β signaling by preventing TGFBR1–TGFBR2 complex formation in specific cell contexts.\",\n      \"evidence\": \"Deletion mutagenesis with Smad2 phosphorylation readouts; GAG-deficient mutants in LLC-PK1 cells with reporter and receptor co-IP assays; recombinant soluble betaglycan characterization by SPR and bioassay\",\n      \"pmids\": [\"11278442\", \"11668175\", \"11256966\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of each domain's ligand binding unknown\", \"How context determines whether betaglycan promotes or inhibits signaling unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"TGF-β and inhibin A were shown to compete for betaglycan binding on gonadotrope cells, with TGF-β reversing inhibin antagonism of activin-induced FSH gene expression, linking the two co-receptor functions through a shared binding surface.\",\n      \"evidence\": \"Radiolabeled inhibin A competition binding, receptor co-IP, and luciferase reporter in LβT2 cells\",\n      \"pmids\": [\"12456797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of competition not resolved at residue level\", \"In vivo physiological significance of TGF-β–inhibin competition for betaglycan undetermined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"MT1-MMP was identified as the protease mediating betaglycan ectodomain shedding, generating a 90 kDa soluble fragment retaining TGF-β2-preferential binding, providing a mechanism for regulated production of the soluble antagonist form.\",\n      \"evidence\": \"Overexpression of MT-MMPs in COS-1 cells with metalloprotease inhibitors and binding competition\",\n      \"pmids\": [\"14672946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological stimuli triggering shedding in vivo not identified\", \"Fate of remaining transmembrane fragment not explored\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The inhibin-binding site was mapped to residues 591–700 within the ZP domain, with Val614 critical for inhibin but not TGF-β binding, enabling functional separation of inhibin co-receptor and TGF-β presentation activities. Separately, betaglycan was found to signal independently of TGF-β ligand through p38 MAPK via its cytoplasmic domain.\",\n      \"evidence\": \"Point mutagenesis (V614Y) with binding and functional reporter assays; adenoviral overexpression with p38 inhibitor and TGF-β blocking antibodies\",\n      \"pmids\": [\"16621788\", \"16413747\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ZP domain–inhibin interface not resolved\", \"Cytoplasmic domain signaling partners for p38 activation unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The reciprocal inhibin epitope for betaglycan binding was mapped to the inhibin α-subunit outer convex surface (Val108–Tyr120), with triple alanine substitution abolishing betaglycan-dependent inhibin suppression of activin-induced FSH release.\",\n      \"evidence\": \"Site-directed mutagenesis of inhibin A with binding assay and pituitary cell FSH bioassay\",\n      \"pmids\": [\"18397882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure of inhibin–betaglycan complex\", \"Whether same epitope mediates inhibin B binding unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"In vivo genetic studies established that betaglycan is required for fetal testis development and dose-sensitively controls kidney morphogenesis, while biophysical studies showed that high-affinity TGF-β binding requires both ectodomain lobes tethered together, with plasmin cleavage between them abolishing neutralizing activity. Betaglycan was confirmed as an obligate endogenous inhibin co-receptor in primary gonadotropes.\",\n      \"evidence\": \"Knockout/heterozygous mice with morphological and molecular phenotyping; plasmin proteolysis with SPR and bioassay; siRNA and neutralizing antibody in primary gonadotropes\",\n      \"pmids\": [\"19696014\", \"21533152\", \"19842711\", \"19372236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Embryonic lethality of null mice limits adult phenotype analysis\", \"Whether developmental phenotypes are TGF-β-, inhibin-, or Wnt-dependent unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Inhibin A was found to antagonize TGF-β2 signaling by inducing clathrin-independent endocytic internalization of betaglycan, reducing surface TGF-β2 binding sites — a mechanism distinct from TGF-β-induced internalization. The transmembrane-cytoplasmic stub remaining after shedding was identified as a γ-secretase substrate whose accumulation blunts TGF-β2 signaling.\",\n      \"evidence\": \"Endocytosis inhibitors and binding assays in adrenocortical cells; γ-secretase inhibitors and reporter assays in HepG2 cells\",\n      \"pmids\": [\"20160125\", \"21167215\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream fate of γ-secretase-released intracellular domain unknown\", \"Whether internalized betaglycan is recycled or degraded unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"The crystal structure of the betaglycan ZP-C domain at 2.0 Å revealed an immunoglobulin-like fold with a convex surface pocket important for TGF-β binding, and explained why betaglycan, lacking the ZP maturation cleavage site, does not polymerize like other ZP proteins.\",\n      \"evidence\": \"X-ray crystallography at 2.0 Å resolution\",\n      \"pmids\": [\"21402931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of full ectodomain or ternary ligand–receptor complex\", \"ZP-C–inhibin binding interface not structurally resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Betaglycan was shown to act as a signaling switch that redirects TGF-β signaling from Smad2/3 toward Smad1/5/8 via ALK1, driving myofibroblast differentiation in lung fibroblasts, with expression upregulated by glucocorticoids.\",\n      \"evidence\": \"Dexamethasone treatment, siRNA, reporter assays, and in vivo mouse lung experiments\",\n      \"pmids\": [\"24347165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ALK1 pathway potentiation by betaglycan unclear\", \"Whether this switch operates in other fibroblast lineages unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"TGFBR3 was found to scaffold a complex with β-arrestin 2 and IκBα to inhibit NF-κB signaling, suppressing EMT and migration in oral cancer cells — a TGF-β-independent signaling mechanism mediated by its cytoplasmic domain.\",\n      \"evidence\": \"Co-immunoprecipitation, overexpression, β-arrestin 2 siRNA, migration/invasion assays\",\n      \"pmids\": [\"29130787\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding between TGFBR3 cytoplasmic domain and β-arrestin 2 not demonstrated with purified proteins\", \"Physiological trigger for this complex formation unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Biophysical studies defined the hand-off mechanism quantitatively: betaglycan binds TGF-β homodimer with 1:1 stoichiometry allowing one TGFBR2 to bind simultaneously, but betaglycan must be displaced for TGFBR1 recruitment. Separately, betaglycan GAG chains were shown to independently regulate Wnt3a signaling, with heparan sulfate and chondroitin sulfate exerting opposing effects.\",\n      \"evidence\": \"SPR, ITC, and SEC for stoichiometry; GAG mutant constructs with Wnt reporter assays\",\n      \"pmids\": [\"27951653\", \"27784788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether hand-off occurs on the plasma membrane in real time not visualized\", \"In vivo relevance of GAG-mediated Wnt regulation not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"NMR and mutagenesis mapped the betaglycan ZP-C binding site on TGF-β2 to the inner concave finger region (Ile-92, Lys-97, Glu-99), explaining isoform selectivity for TGF-βs and inhibin A over BMPs. Conditional gonadotrope knockout confirmed TGFBR3 as an inhibin A-specific (not inhibin B) co-receptor in vivo, with knockout females showing super-fertility.\",\n      \"evidence\": \"NMR titrations, SPR, site-directed mutagenesis; conditional Cre-lox gonadotrope knockout with FSH assays\",\n      \"pmids\": [\"30598510\", \"30364975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length betaglycan–TGF-β2 co-structure still lacking at this point\", \"Mechanism of inhibin A vs. inhibin B selectivity at structural level unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Cryo-EM structure of TGF-β bound simultaneously to betaglycan and TGFBR1/TGFBR2 provided near-atomic resolution of the hand-off mechanism, revealing how betaglycan engages TGF-β at interfaces distinct from endoglin and is displaced upon signaling receptor assembly.\",\n      \"evidence\": \"Cryo-EM structural determination with functional validation\",\n      \"pmids\": [\"40011426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of betaglycan–inhibin–ActRII ternary complex not yet determined\", \"Role of GAG chains in the structural assembly not visualized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of the inhibin A–betaglycan–ActRII ternary complex, the identity of cytoplasmic domain binding partners mediating p38 MAPK and β-arrestin 2 signaling, the physiological contexts governing whether betaglycan promotes versus inhibits TGF-β signaling, and the in vivo significance of GAG-mediated Wnt regulation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of inhibin–betaglycan–ActRII complex\", \"Cytoplasmic domain signaling partners not identified by unbiased approaches\", \"Context-dependent switch between positive and negative TGF-β regulation not mechanistically resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 15, 17]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 4, 6, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 7, 8, 30]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 4]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 3, 7, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 8, 12, 15, 18, 33]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [28, 29]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [21, 28]}\n    ],\n    \"complexes\": [\n      \"TGF-β–betaglycan–TGFBR2 ternary complex\",\n      \"Inhibin A–betaglycan–ActRII ternary complex\",\n      \"Betaglycan–endoglin complex\",\n      \"Betaglycan–β-arrestin 2–IκBα complex\"\n    ],\n    \"partners\": [\n      \"TGFBR2\",\n      \"TGFBR1\",\n      \"ACVR2A\",\n      \"ENG\",\n      \"ARRB2\",\n      \"INHA\",\n      \"MMP14\",\n      \"GIPC1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}